Аssociation between (rs1024611) -12518A/G CCL2 gene polymorphism and serum level of C-reactive protein with different clinical and serological phenotypes of systemic sclerosis in the Russian cohort of patients

It has been established that polymorphisms of inflammatory mediator genes, tissue matrix proteins and growth factors are involved in autoimmune and fibrotic processes in systemic scleroderma (SSc). CCL2 chemokine is a key inflammatory protein present in the circulating blood and in the lesions of the skin of patients with SSc. The purpose of this study was to study the association of the polymorphism -2518 A / G of the CCL2 gene with C-reactive protein (CRP) levels among patients with different clinical and serological phenotypes of SJS. In the general group of patients, carriers of the genotype -2518AA had a statistically significant higher average CRP level compared to carriers of the -2518G allele (AG + GG genotypes) (p = 0.032). Similar differences in CRP levels were obtained in patients with a diffuse form of SJS and in patients with positive antibody titers to topoisomerase I (p = 0.041 and p = 0.042, respectively). Conclusions: The carriage of the -2518AA genotype was significantly associated with a high level of CRP in patients with poor prognosis of SSc (presence of a diffuse form and seropositive autoantibody titers to topoisomerase I) compared with patients carrying the -2518G allele. Polymorphism -2518A / G of the CCL2 gene can be used as a genetic marker of severity and poor prognosis for SSc.

системный склероз, диффузная форма системного склероза, интерстициальное поражение легких, полиморфизм гена CCL2, уровни С-реактивного белка, аутоантитела к топоизомеразе I, systemic sclerosis, diffuse form systemic sclerosis (dcSSc), interstitial lung disease (ILD), CCL2 gene polymorphism, C-reactive protein levels, anti-topoisomerase I antibodies (ATA)